France
· Delayed Price · Currency is EUR AB Science Company Description
AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France.
The company’s lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer’s disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19.
It also developing AB8939, a microtubule destabiliser for acute myeloid leukemia. The company markets its masitinib under the Masivet brand in Europe.
AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.
| Country | France |
| Founded | 2001 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 57 |
| CEO | Alain Moussy |
Contact Details
Address: 3, avenue George V Paris, Ile-de-France 75008 France | |
| Phone | 33 1 47 20 00 14 |
| Website | ab-science.com |
Stock Details
| Ticker Symbol | AB |
| Exchange | Euronext Paris |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | FR0010557264 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Alain Moussy MBA | Co-Founder, Chairman, President, Chief Executive Officer, MD and Scientific Director |
| Laurent Guy MBA | Chief Financial Officer |
| Christian FASSOTTE | Global Chief Medical Officer |
| Alexis BERNARD | Head of Veterinary Sales |
| Harshad KULKARNI | Head of Statistics |
| Dr. Albert Ahn D.V.M. | President of USA Operations |